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Abstract 
To assess the excess risk of HPV-associated cancer (HPVaC) in two at-risk groups – women with a previous 
diagnosis of high grade cervical intraepithelial neoplasia (CIN3) and both men and women treated for non-
cervical pre-invasive ano-genital disease. All CIN3 cases diagnosed in 1989-2015 in Scotland were extracted 
from the Scottish cancer registry (SMR06). All cases of pre-invasive penile, anal, vulval, and vaginal disease 
diagnosed in 1990-2015 were identified within the NHS pathology databases in the two largest NHS health 
boards in Scotland. Both were linked to SMR06 to extract subsequent incidence of HPVaC following the 
diagnosis of CIN3 or pre-invasive disease. Standardised incidence ratios were calculated for the risk of 
acquiring HPVaC for the two at-risk groups compared with the general Scottish population. Among 69714 
females in Scotland diagnosed with CIN3 (890360.9 person-years), 179 developed non-cervical HPVaC. CIN3 
cases were at 3.2-fold (95% CI: 2.7 to 3.7) increased risk of developing non-cervical HPVaC, compared to the 
general female population. Among 1235 patients diagnosed with non-cervical pre-invasive disease (9667.4 
person-years), 47 developed HPVaC. Individuals with non-cervical pre-invasive disease had a substantially 
increased risk of developing HPVaC - 15.5-fold (95% CI: 11.1 to 21.1) increased risk for females and 28-fold 
(11.3 to 57.7) increased risk for males. We report a significant additional risk of HPV-associated cancer in those 
have been diagnosed with pre-invasive HPV-associated lesions including but not confined to the cervix. 
Uncovering the natural history of pre-invasive disease has potential for determining screening, prevention and 
treatment.  
 
Summary box 
What is already known? 
A history of CIN3 confers a significant risk of HPV-associated cancer. 
What is this study adds? 
A history of non-cervical ano-genital pre-invasive disease is associated with significant additional risk of HPV 
associated cancer. 
Determining risk of pre-invasive disease has potential for determining screening, prevention and treatment 
strategies. HPV vaccination for this high-risk group may provide benefit.  
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Introduction 
The incidence of human papillomavirus (HPV)-associated, non-cervical cancers is increasing globally and 
Scotland is no exception. The increase in incidence of oropharyngeal cancer (OPC) has been the best 
documented and evidence that the HPV positive status in OPC confers an improved clinical outcome has 
focused much research into finding an explanation for this observation. However, other non-cervical genital 
HPV associated cancers are also increasing and this is less documented in the literature as is, arguably, the role 
of HPV status in the clinical outcome of those affected.  In Scotland, the age-standardised incidence of cancers 
of the anus, penis, vagina and vulva rose by 1.6, 1.1, 0.1 and 0.9 per 100,000 respectively during 1970 – 2014 
[1]. This trend is mirrored elsewhere in countries that have robust cancer registry data [2]. 
Reasons for the increase in cancers of the anus, penis and vulva are not fully understood although an increase 
in HPV infection supported by temporal changes in sexual practices and behaviors has been suggested. 
Individuals interviewed as part of the National Survey of Sexual Attitudes and Lifestyles (NATSAL) report 
younger age of first intercourse, increased number of lifetime heterosexual partners and an increase in the 
number of individuals reporting same-sex experience compared to earlier surveys [3]. In the USA, inferred 
trends in sexual behaviour over the past decades have paralleled the increasing incidence of HPV-related 
cancers [4]. This said, the differential influence of risk factors, including and beyond sexual behaviours makes 
the generation of a broad conclusion to explain this increase challenging. 
It is important to monitor incidence of these neoplasms to determine the associated morbidity and mortality 
that could be preventable by HPV vaccination in future generations. However, the current HPV vaccines will 
not wholly protect individuals already infected with HPV, nor prevent disease associated with all 13 oncogenic 
types. As a consequence, the challenge remains of how to optimally manage and treat what can be particularly 
morbid cancers from a clinical and psychological perspective. To this end, a clear understanding of their 
epidemiology will help inform the requirement and nature of interventions for their detection, management 
and treatment. 
The national organized cervical screening programme was introduced in Scotland in 1988 with the aim of 
reducing the incidence of invasive cancer of the cervix and has been a success. The European age standardized 
rate of invasive cervical cancer has reduced from 18/100,000 in 1988 to 10/100,000 in 2009, rising 
subsequently to 13/100,000 in 2015. The percentage of eligible women who were recorded as screened 
adequately was 73.4% [4]. However, in Scotland there is currently no coordinated/ organized surveillance for 
non-cervical genital cancers in any population group or guidance for surveillance of these sites in high risk 
groups except for enhanced cervical screening in HIV-positive women. This raises the concern that early 
diagnosis of curable non-cervical genital cancers may be missed despite individuals being seen regularly by 
medical services.  Furthermore, gaining an understanding of particular groups who may be at increased risk of 
non-cervical genital cancers could aid a focused and standardised approach to the monitoring. 
We have used national population data available in Scotland to systematically assess the excess risk of HPV-
associated disease compared to the general population in two populations perceived to be at additional risk of 
associated disease: (a) women with a history of CIN 3 and (b) individuals with a history of non-cervical pre-
invasive disease.   
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Methods 
Data collation for women diagnosed with CIN3 and assessment of subsequent cancer risk 
A retrospective cohort study of national data was performed in order to estimate the risk of HPV associated 
cancers (HPVaC) in those diagnosed with CIN 3.  All individuals resident in Scotland are uniquely identified in 
National Health Service (NHS) datasets via their community health index (CHI) number.   All cases of CIN3 
(ICD10: 233.1) were extracted from the Scottish Cancer Registry (SMR06) [6].  As full introduction of national 
cervical cancer screening was introduced in 1988 [5], extraction of CIN3 from SMR06 was limited to Jan 1989 - 
Dec 2015 (with the latter year representing the most recent year for which data was available at time of 
extraction). Variables collected were gender, date of birth, health board and date of diagnosis of CIN3. All 
individuals with CIN3 were then linked to SMR06 to extract incidence of HPVaC (tonsil, base of tongue, soft 
palate, oropharynx not otherwise specified, cervix, vulva, vagina, penis, anus) (ICD10: C09, C01, C05, C10, C53, 
C51, C52, C60, C21, respectively) in addition to rectal cancer (ICD10: C20) which was used as a baseline 
comparator with no known association with HPV.  Cancers with evidence of both vaginal and cervical 
malignancy were classified as cervical cancer. The analysis focussed on individuals over 18 years old given that 
over 95% of cancers listed above are diagnosed after this age [1].  Date of death/emigration was also captured 
in order to obtain the date of censoring due to loss of follow-up. 
 
Data collation for individuals diagnosed with pre-invasive penile, anal, vulval and vaginal disease and 
assessment of subsequent cancer risk 
All cases of pre-invasive penile, anal, vulval and vaginal disease and invasive malignancy diagnosed between 
1990 and 2015 were identified within the NHS pathology databases associated with the two largest health 
boards in Scotland – NHS Greater Glasgow and Clyde (GGC) and NHS Lothian that together cover 2 million 
people and thus around 40% of the Scottish population. Data, collected as part of routine clinical care, on 
gender, date of birth, health board, date of diagnosis and degree of dysplasia were extracted. Subsequent 
HPVaC, rectal cancer and date of death/emigration were linked from national data as explained previously. 
 
Statistical analysis 
For each of the two at-risk populations, person time at risk and the number of observed cancers were 
stratified by age group in 5 year bands (18-19, 20-24, 25-30,…, 84-89, 90+), gender and year of diagnosis. The 
expected numbers of cancers occurring among the at-risk population, assuming the same incidence as that 
observed for the general population in Scotland (for patients with CIN3 history) or in GGC and Lothian (for pre-
invasive cohort) stratified by the same age groups, gender and year of cancer diagnosis, was calculated by 
multiplying the person time at risk in each group by the corresponding average cancer incidence. The 
Standardised Incidence Ratio (SIR) was defined as the ratio of the observed to expected number of cancers and 
the confidence interval (CI) was calculated assuming that the observed number followed a Poisson 
distribution. 
We excluded patients with a diagnosis of any HPVaC before a diagnosis of CIN3 or pre-invasive non-cervical 
disease. The person time at risk started counting at one year after CIN3 or pre-invasive non-cervical disease 
diagnosis and ended at earlier incidence of first HPVaC, death, emigration or the end of study (2015-12-31). 
Those with an HPVaC occurring within one year of CIN3 or pre-invasive non-cervical disease diagnosis were 
excluded in the baseline analysis to avoid mis-classification of concurrent disease as sequential disease events. 
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A sensitivity analysis, considering an exclusion time of 0, 3, 6, 9 months, was conducted to examine the 
influence of this exclusion upon the results. 
All analysis was conducted using R version 3.2.1.  
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Results 
Risk of HPVaC following CIN3 diagnosis 
Overall, 72153 women in Scotland had a diagnosis of CIN3 recoded in SMR06 between 1989-2015. Figure 1 
presents the denominators of the at-risk populations, related exclusions and start and end point(s) of the 
analysis. After excluding the patients with HPVaC before or during the year directly after the diagnosis of CIN3, 
the denominator reduced to 69714, contributing 890360.9 person years (Table 1). The CIN3 population had a 
median of age of diagnosis of 30 (IQR 26-36) and of these 490 women had a diagnosis of any HPVaC more than 
one year after diagnosis of CIN3 corresponding to an SIR of 2.3 (95% CI 2.1-2.5) compared to the general 
female population in Scotland (Table 1). 
The risk of developing a non-cervical HPVaC varied by the anatomical subtype - SIR ranged from 2.3 (95% CI 
1.6-3.2) for oropharyngeal cancer to 9.6 (95% CI 7-13) for vaginal cancer (Table 1).  The risk among women 
with CIN3 for anal and vulvar cancer was increased by more than 2-fold compared to the general female 
population.  The SIR for non-HPV related rectal cancer did not differ substantially from unity (SIR = 1.1 95% CI 
0.9-1.5) (Table 1).   
The SIR for developing any non-cervical HPVaC in the context of a cervical screening programme was higher 
than that for cervical cancers (SIR for non-cervical HPVaC = 3.2, 95% CI 2.7-3.7; SIR for cervical cancer = 2.0, 
95% CI 1.8-2.2) (Table 2).  The SIR for non-cervical HPVaC increased with age at diagnosis CIN3 (SIR = 3.1 95% 
CI 2.2-4.1 for age <=30; SIR = 7.4 95% CI 0.9-26.8 for age >70).  There was no time trend identified for the risk 
of non-cervical HPVaC by year of diagnosis of CIN3. Interestingly, there was no reduction in risk of developing a 
non-cervical HPVaC with increasing time from CIN3 diagnosis; the risk between 1-2 years from CIN3 diagnosis 
was similar to that more than 20 years after CIN3 diagnosis. 
The risk of cervical cancer was significantly increased in all birth cohorts, except for the women born after 
1965, for whom the risk did not differ from the general population. The greatest risk of cervical cancer was 
observed in the oldest cohort (women born before 1935: SIR = 10.1 95% CI 5.8-16.4; born 1936-1945: SIR = 7.4 
95% CI 5-10.4). The risk of cervical cancer was increased in all ages when diagnosed after 30 years, with an 
increasing SIR for those diagnosed CIN3 at older age (SIR = 2.5 95% CI 2.1-3 for age 31-40; SIR = 14.3 95% CI 
1.7-51.6 for age >70).  There was no time trend observed in SIR by year of diagnosis of CIN3 and there was no 
decreasing trend in SIR for time since the CIN3 diagnosis – even after 20 years since diagnosis of CIN3 there 
remained an increased risk of cervical cancer (SIR = 2.6, 95% CI 1.6-4.1). 
 
Risk of HPVaC following after non-cervical pre-invasive disease 
Overall, 2309 patients had a diagnosis of pre-invasive (all degrees of dysplasia) and invasive penile, anal, vulvar 
and vaginal disease in GGC and Lothian. After excluding the patients with HPVaC before or during the year 
directly after the diagnosis of pre-invasive disease, the denominator for analysis reduced to 1235 (Figure 1). 
For each anatomical site of dysplasia, the majority were classified as severe dysplasia or dysplasia NOS (n=782, 
63.3%) with a small proportion classified as having mild or moderate dysplasia (Table A2). For the cohort of 
each dysplasia site, the median age ranged from 41 (Interquartile range (IQR) 35-47) year for female perineum 
and 57 (IQR 39-64.5) years for penis (Table A2). 
Overall 1035 women had pre-invasive disease in the ano-genital region (vagina, vulva, perineum and anus), 
contributing 8464.5 person years of follow-up (Table 3). Among them, 40 developed HPVaC one year or more 
after the diagnosis of pre-invasive ano-genital disease. Compared to the general female population resident in 
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GGC and Lothian, the incidence of HPVaC for women with a history of pre-invasive disease was 15.5 times 
higher (95% CI 11.1-21.1). The SIR was highest for the patients with anal dysplasia (SIR = 38.9 95% CI 15.6-80.1) 
but lower for those with vaginal dysplasia (SIR = 9.4 95% CI 4.3-17.8). 
198 male patients had pre-invasive anogenital disease (penis, perineum and anus), contributing 1202.9 person 
years (Table 3). Among them, 7 developed HPVaC one year or more after the diagnosis of pre-invasive disease. 
Compared to the male population resident in GGC and Lothian, the SIR for men with a history of pre-invasive 
ano-genital disease to develop HPVaC was 28 (95% CI 11.3-57.7). The risk of cancer was highest for the 
patients with anal dysplasia (SIR = 36.4 95% CI 9.9-93.1) and lowest for those with penile dysplasia (SIR = 21.4 
95% CI 4.4-62.6). 
 
Sensitivity analysis 
Sensitivity analysis was conducted for the CIN3 cohort to investigate the effect of changing the cancer 
exclusion period from the baseline choice of 1 year to 0, 3, 6 or 9 months. If no exclusion was applied, 631 
cervical cancer cases were observed among CIN3 patients (SIR = 3.8), likely representing concurrent diagnosis. 
When a 3 months exclusion period was used, 374 cervical cancer cases were observed (SIR = 2.3) – similar to 
baseline analysis of 1 year (SIR = 2).  The SIR did not materially change for developing non-cervical genital 
cancers when different exclusion periods were applied (Table A1). 
For the non-cervical pre-invasive cohort, 741 patients with prior HPVaC were excluded for the following 
reasons: 1) the site of the pre-invasive disease matched the site of the prior HPVaC (Table A3); 2) The time 
difference between the diagnosis of pre-invasive and prior HPVaC was short (median 60 days IQR 20-238). 
Sensitivity analysis was performed again changing the exclusion period from 1 year to 0, 3, 6 and 9 months. 
SIRs for exclusion period of 3, 6 and 9 months were close to the baseline results (Table A4). However if no 
exclusion period was applied, a higher number of subsequent HPVaC cases was observed and the SIR inflated 
substantially compared to the baseline analysis.  
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Discussion 
In the present evaluation which spanned 36 years and incorporated national data, we describe two groups at 
substantially increased risk of HPV associated cancer: those who have been diagnosed with high grade cervical 
lesions and those who have been treated for non-cervical pre-invasive disease to any degree.  Notably, women 
who have had a CIN3 diagnosis (identified via screening) were at 3.2 fold increased risk of developing a non-
cervical HPVaC (including a 9.6-fold risk of developing vaginal cancer) compared to the general female 
population in Scotland. In addition, individuals with non-cervical pre-invasive disease had a substantially 
increased risk of developing HPVaC, reflected as a 15.5 fold and 28 fold increased risk for females and males 
respectively compared to the general population. The additional risk was highest in patients with pre-invasive 
disease of the anus for both genders. 
In women diagnosed with CIN3, the greatest risk of both non-cervical and cervical HPVaC was associated with 
older age at diagnosis but the magnitude of that risk was unaffected by time since diagnoses. 
The observation that a history of CIN3 confers a significant risk of HPV associated cancer is consistent with 
other studies [7-14] such as the one performed by Kalliala and colleagues [10] who reported SIRs for vulvar, 
vaginal and anal canal cancer as 4.1 (95% CI: 1.5-8.9), 12 (2.9-28) and 5.7 (1.2-17) respectively. Strander et al 
[11] also reported SIRs for cervical and vaginal cancer as 2.3 (2.2-2.5) and 6.8 (5.6-8.2). Ebisch et al [14] 
reported incidence rate ratios for anal, vulvar, vaginal and oropharyngeal cancer as 3.9 (2.3-6.4), 5 (3.3-7.6), 
86.1 (12-618.1) and 5.5 (1.2-24.8). In our study, SIRs for cervical, vulvar, vaginal and anal cancer were 2 (1.8-
2.2), 2.8 (2.2-3.6), 9.6 (7-13), and 2.6 (1.9-3.6), which are in line with the Nordic studies [10,11], 
notwithstanding the fact that the authors did not exclude the patients with a previous diagnosis of HPVaC as 
we have in the present analysis. Strander et al and Ebisch et al document a duration of risk of at least 20 years, 
similar to the present findings [11,12,14].  
The risk of HPV associated cancer in those with non-cervical pre-invasive disease is not well documented in the 
literature in contrast to the risk after CIN3. There is a particular paucity of studies which have taken into 
account large national data sets; rather the existing literature has focussed more on small cohort studies of 
HPV associated disease progression at a particular site with no comparator/control group [15,16]. Joura et al 
[17] reported that compared with those who underwent cervical surgery, those who were diagnosed with 
vulvar disease were at nearly 3 fold increased risk of developing any subsequent HPV related disease. To our 
knowledge the present analysis represents the first population based study of risk with 
comparison/contextualisation to the general population. 
Ideally, screening or surveillance guidelines and management strategies should take into account the 
additional risks conferred on those with pre-invasive disease. This is easier to apply for cervical disease given 
the existence of an organised screening programme.  Most countries that offer cervical screening now offer 
molecular HPV testing as part of post treatment follow up of CIN [18]. Further developments in the cervical 
screening in the UK (and beyond) which include the implementation of primary screening using molecular HPV 
testing are likely to identify those at risk of subsequent cervical disease earlier as demonstrated in trials of HPV 
vs Cytology screening, [19,20]. The sensitivity and earlier “warning” signal of an HPV test may thus deliver 
benefits to those with (any) HPV associated pre-invasive disease although this was not specifically investigated 
in the aforementioned trials. Furthermore, treatment for women with CIN3 by the gynaecologists should also 
include inspection of vaginal, vulva and perineum. 
The most effective strategy to manage non-cervical HPV associated disease is more challenging.  There is no 
population based screening programme or surveillance for AIN in Scotland, and so the risks reported in this 
study are likely to underestimate its occurrence. Screening for anal disease has been considered using a variety 
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of approaches (cytology, high resolution anoscopy, HPV testing, biomarkers and various combinations 
thereof). However, currently, there is no evidenced, effective model for an anal screening and treatment 
pathway that would reduce risk of anal cancer. Given that treatment of anal lesions is associated with 
significant morbidity, further research is required. Longitudinal studies such as the Australian Study of the 
Prevention of anal cancer “SPANC” which monitors viral,  cytopathological and anoscopy outcomes over time 
in an MSM population will be helpful in this regard  [21,22]. 
Notwithstanding the limitations of the data on anal screening, arguably considerably more attention and 
research has been channelled into this area compared to screening for other non-cervical HPV associated 
cancers. This is likely attributable to the comparative rarity of penile, vulvar, & vaginal cancer, and the fact that 
OPC does not have a monitorable precursor phase, with patients presenting with symptomatic disease.  
Kreimer et al [23,24] showed that HPV-16 E6 serology can identify those at greater risk of subsequent anal and 
oropharyngeal cancer but not other HPV associated cancers; HPV16 E6 seropositivity was present in 29.2% of 
individuals who later developed anal cancer compared with 0.6% of controls [24] and in the prediagnostic 
samples of 34.8% of patients with oropharyngeal cancer and 0.6% of controls [23].   
Another important point for consideration is why those with preinvasive lesions are at additional risk of 
subsequent cancer.  Part of this explanation could of course be to do with the continuation of risk-associated 
behaviours after the initial diagnosis (including the key factors of smoking and social deprivation) which we did 
not assess in this study. Similarly, while Strander et al [12] adjusted for follow-up duration, treatment period, 
and age at treatment the authors did not adjust for behavioural/environmental influences. This said, the CIN3 
population described in the present analysis represented women who were engaged in cervical screening. The 
study population was thus biased towards those from less deprived backgrounds with a lower risk of HPV 
infection and disease [25].  However, future studies which endeavour to capture behavioural data or 
surrogates will be important to (a) determine the key behavioural factors that confer risk of subsequent 
disease which could inform focussed management (b) quantify the extent of risk which remains after 
adjustment for such factors. With respect to the latter, it is entirely plausible that the efficacy and capacity of 
innate immune responses play a continued role in the susceptibility to HPV associated disease [26]. Only 5% of 
those infected with HR-HPV develop high grade cervical lesions the majority of which will resolve naturally, but 
immunocompromised patients have a higher risk of developing high grade disease [27-30]. However, the lack 
of understanding of the mechanisms determining persistence makes development of a therapeutic vaccine 
challenging. A further factor is the widespread colonisation of ano-genital, perineal and oral squamous mucosa 
by HPV. Treatment at one site in the absence of other measures to promote HPV clearance will not affect HPV 
burden at other infected sites, and so will not mitigate the risk of subsequent disease  
Although current HPV vaccines are delivered as prophylactic regimens i.e. before HPV infection, there may be 
merit in vaccinating high-risk groups with preinvasive lesions. It is possible to stimulate HPV-specific antibodies 
in older women who have previously been diagnosed with abnormal pap smears through quadrivalent 
vaccination [31]. Furthermore, adjuvant administration of quadrivalent HPV vaccine has been shown to be 
associated with a significant reduction in recurrent high-grade anal intraepithelial neoplasia (HGAIN) in MSM 
[32]. Joura et al demonstrated a significant reduction in HPV related vulvo-vaginal disease in women who had 
been both vaccinated and also treated following vaccination for cervical disease [17]. Opportunistic HPV 
vaccination for our high-risk populations may prove to be beneficial in preventing subsequent development of 
HPV-related cancers, while gender-neutral HPV immunisation is associated with profound decreases in most of 
the clinically relevant oncogenic HPV types and will significantly reduce risk of HPVaC in men and women with 
preinvasive non-cervical ano-genital disease [33]. 
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In summary in this analysis we demonstrate the significant additional risk of HPV associated cancer in 
individuals who have been diagnosed with preinvasive lesions including but not confined to the cervix. Further 
investigation into mechanistic and behavioural drivers that explain this phenomenon will inform screening and 
therapeutic strategies.  Given the increasing incidence of HPV associated cancers in genital and non-genital 
sites within unvaccinated populations, this should be a priority for research. 
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Table1: Risk of HPV associated cancer (HPVaC) among women with previous CIN3 compared to general female population in Scotland 1989-2015 
Cancer type Observed no Expected no Person years SIR1 (95% CI) 
HPVaC2 490 212.0 890360.9 2.3 (2.1-2.5) 
Non-cervical HPVaC3 179 56.7 892767.9 3.2 (2.7-3.7) 
Anus 37 14 893622.2 2.6 (1.9-3.6) 
Cervix 311 155.8 891384.5 2 (1.8-2.2) 
Vagina 43 4.5 893547 9.6 (7-13) 
Vulva 62 22.2 893306.3 2.8 (2.2-3.6) 
OPC4 (NOS5 and sites below) 37 16.1 893666.8 2.3 (1.6-3.2) 
Base of tongue 11 4.1 893750.3 2.7 (1.4-4.8) 
Soft palate 5 3.6 893779.4 1.4 (0.5-3.3) 
Tonsil 17 6.3 893733 2.7 (1.6-4.3) 
Oropharynx NOS 4 2.2 893779 1.9 (0.5-4.7) 
Non HPV related – rectal cancer 58 50.9 893423.5 1.1 (0.9-1.5) 
 
1SIR: standard incidence ratio. 
2HPVaC includes tonsil, base of tongue, soft palate, oropharynx not otherwise specified, cervix, vulva, vagina, penis and anus. 
3Non-cervical HPVaC NOS includes tonsil, base of tongue, soft palate, oropharynx not otherwise specified, vulva, vagina, penis and anus. 
4OPC: oropharyngeal cancer. 
5NOS: not otherwise specified. 
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Table 2: Risk of cervical cancer and non-cervical HPVaC among women with previous CIN3 in Scotland 1989-2015 by birth cohort, age at, incidence 
period and time since CIN3 diagnosis 
  
 Cervical cancer  Non-cervical HPVaC 
Variables level 
 Observed 
no 
Expected 
no 
Person 
years SIR (95% CI) 
 Observed 
no 
Expected 
no 
Person 
years SIR (95% CI) 
all cases 
 
 311 155.8 891384.5 2 (1.8-2.2)  179 56.7 892767.9 3.2 (2.7-3.7) 
Birth cohort <=1935  16 1.6 9962.8 10.1 (5.8-16.4)  9 2.2 9941.2 4.2 (1.9-7.9) 
 
(1935,1945]  32 4.3 32494 7.4 (5-10.4)  25 5.4 32664.9 4.7 (3-6.9) 
 
(1945,1955]  73 16.4 110547.3 4.5 (3.5-5.6)  42 13.8 110860.4 3.1 (2.2-4.1) 
 
(1955,1965]  108 47.4 283377 2.3 (1.9-2.8)  64 21.2 284012.8 3 (2.3-3) 
 
(1965,1975]  65 59.7 313826.5 1.1 (0.8-1.4)  35 12.5 314075.7 2.8 (2-3.9) 
 
>1975  17 26.4 141176.8 0.6 (0.4-1)  4 1.6 141212.9 2.5 (0.7-6.3) 
Age at CIN3 <=30  51 81.2 445537.5 0.6 (0.5-0.8)  42 13.7 445736.6 3.1 (2.2-4.1) 
 
(30,40]  140 55.8 311578.4 2.5 (2.1-3)  66 23.3 312275.5 2.8 (2.2-3.6) 
 
(40,50]  67 14.3 100429.4 4.7 (3.6-6)  36 13.0 100824.7 2.8 (1.9-3.8) 
 
(50,60]  40 3.7 28228.4 10.9 (7.8-14.8)  27 5.2 28298.2 5.2 (3.4-7.6) 
 
(60,70]  11 0.7 4757.5 14.9 (7.4-26.6)  6 1.1 4787.2 5.4 (2-11.8) 
 
>70  2 0.1 853.3 14.3 (1.7-51.6)  2 0.3 845.6 7.4 (0.9-26.8) 
Year of CIN3 <=1995  128 69.6 419083.9 1.8 (1.5-2.2)  103 32.4 419577.1 3.2 (2.6-3.9) 
 
(1995,2000]  86 37.7 215755.7 2.3 (1.8-2.8)  40 13.3 216370.0 3 (2.2-4.1) 
 
(2000,2005]  52 28.8 151861.1 1.8 (1.4-2.4)  23 7.3 152027.1 3.2 (2-4.73) 
 
(2005,2010]  38 16.2 84666.8 2.4 (1.7-3.2)  11 3.1 84767.5 3.5 (1.8-6.3) 
 
>2010  7 3.6 20016.9 2 (0.8-4.1)  2 0.5 20026.4 3.0 (0.5-13.9) 
Years since CIN3 1-<2  48 16.8 101870.2 2.9 (2.1-3.8)  8 2.5 101916.7 3.2 (1.4-6.3) 
 
2-4  54 33 184768.4 1.6 (1.2-2.1)  17 5.8 184969.7 2.9 (1.7-4.7) 
 
5-9  99 47.6 252119.3 2.1 (1.7-2.5)  40 12.1 252567.1 3.3 (2.4-4.5) 
 
10-14  59 32.3 183521 1.8 (1.4-2.4)  45 14.5 183930.9 3.1 (2.3-4.2) 
 
15-19  32 18.8 116394.2 1.7 (1.2-2.4)  44 13.6 116625.1 3.2 (2.4-4.4) 
 
>=20  19 7.3 52711.4 2.6 (1.6-4.1)  25 8.2 52758.5 3.1 (2-4.5) 
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Table 3: Risk of HPVaC among people with non-cervical pre-invasive disease in genital area for each dysplasia site compared to general population in 
GGC/Lothian 1990-2015 
Gender Dysplasia site N Observed no Expected no Person years SIR (95% CI) 
female anus 117 7 0.2 548.5 38.9 (15.6-80.1) 
 
vagina 307 9 1.0 3286.1 9.4 (4.3-17.8) 
 
vulva 590 23 1.4 4476.9 16.6 (10.5-24.8) 
 
perineum 21 1 0.1 152.1 20 (0.5-111.4) 
 
pan-perineum1 1035 40 2.6 8464.5 15.5 (11.1-21.1) 
male penis 95 3 0.1 517.4 21.4 (4.4-62.6) 
 
anus 102 4 0.1 681.2 36.4 (9.9-93.1) 
 
pan-perineum2 198 7 0.3 1202.9 28 (11.3-57.7) 
1anus, vagina, vulva, perineum 
 2penis, anus, perineum 
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Reasons for the global increase in non-cervical genital cancers are not fully understood, although an increase in human papillomavirus (HPV) infection has been suggested as one possible cause. The present evaluation, which spans more than three decades in Scotland, identifies two groups at substantially increased risk of HPV-associated cancer: women who have been diagnosed with high grade cervical lesions and individuals who have been treated for non-cervical pre-invasive disease. The findings suggest that determining the risk of pre-invasive disease may aid the development of screening, prevention, and treatment strategies, with HPV vaccination of potential benefit for this high-risk group.        
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